EXUMA Biotech
PrivateLast Round
Series B
Aug 20, 2026
Total Funding Raised
$97M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
EXUMA Biotech is a biotechnology company that discovers and develops CAR-T cell therapies and delivery solutions for the treatment of solid and liquid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EXUMA Biotech Comparables
Compare EXUMA Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AbbVie | 86% | |
| AffyImmune Therapeutics | 83% | |
| Alaya.bio | 83% |
EXUMA Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 20, 2026 | ||||
| Series B Extension | Dec 21, 2021 | ||||
| Series B | Mar 12, 2020 | ||||
| VC Round | Jan 7, 2018 | ||||
| Series A | Jan 6, 2017 |
Key People
Founding team and executive leadership
EXUMA Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SunTerra Capital | VC Round, Series A |
| Sinobioway Group | VC Round, Series A |
| BDT & MSD Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
$70M round completed.
- Jan 23, 2025
Presented at the ASCO GI 2025 symposium.
Recent news
Latest coverage and updates
- is_developingJul 6, 2026
Exumabio is developing scalable, tumor-specific, and point-of-care delivery platforms.
EXUMA Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about EXUMA Biotech's valuation, stock price, and market status.
Is EXUMA Biotech a public or private company?
EXUMA Biotech is a private company.
What is the current stock price of EXUMA Biotech?
EXUMA Biotech is a private company with no public stock price. No recent secondary market data is available.
How much is EXUMA Biotech worth (valuation)?
Valuation information for EXUMA Biotech is not publicly available.
Can I buy EXUMA Biotech stock?
EXUMA Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was EXUMA Biotech's last funding round?
EXUMA Biotech's most recent funding round was Series B on December 21, 2021.
Who are the main investors in EXUMA Biotech?
Key investors in EXUMA Biotech include SunTerra Capital, Sinobioway Group.
Will EXUMA Biotech IPO soon?
No public IPO plans have been announced for EXUMA Biotech.
How can I track EXUMA Biotech secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EXUMA Biotech's secondary market activity and sign up for updates.